Drugs in ATC Class B05A

Up to Top Level ATC Classes

Up to B - Blood and blood forming organs

Up to B05 - BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS

Subclasses in ATC: B05A - BLOOD AND RELATED PRODUCTS

B05AA - Blood substitutes and plasma protein fractions

B05A Market Analysis and Financial Projection

The global market for ATC Class B05A (Blood and Related Products) is experiencing robust growth driven by clinical demand, technological innovations, and expanding applications in transfusion medicine. Concurrently, the patent landscape reflects intense R&D activity to address supply challenges and advance synthetic alternatives. Below is a detailed analysis of both market dynamics and intellectual property trends:

---

Market Dynamics

Growth Drivers

• Rising Demand for Transfusions: Surging surgical procedures, trauma cases, and chronic diseases (e.g., anemia, cancer) are fueling demand for red blood cells (RBCs), platelets, and plasma products. RBCs dominate the market due to their critical role in treating acute blood loss[7][8].
• Aging Population: By 2050, 2 billion people will be over 65, increasing demand for blood products in age-related disorders[8].
• Automation: Innovations like automated blood processing reduce human error and enhance efficiency in component separation (e.g., plasma, platelets)[2][8].
• Plasma-Derived Therapies: Plasma products for immune disorders and hemophilia are growing at a 6.6% CAGR, projected to reach $45.7 billion by 2027[11].

Market Segmentation

• By Product:	Product	Market Share	Growth Drivers
  Red Blood Cells	Dominant	Trauma, surgeries, anemia
  Fresh Frozen Plasma	Fastest CAGR	Critical care, clotting disorders
  Platelets	Steady	Cancer treatments

• By End User:
  • Blood Banks: Largest segment (storage and distribution)[2].
  • Hospitals: Growing due to surgical and trauma care needs[7].

Regional Insights

• Asia-Pacific: Fastest-growing region (India alone requires ~14.6 million transfusions annually)[7].
• North America/Europe: Lead in plasma-derived therapies and RBC innovations[8][11].

---

Patent Landscape

Key Innovations

1. Artificial Blood Substitutes:

   • Hemoglobin-Based Carriers: Patents focus on cross-linked hemoglobin solutions (e.g., US6914127) to mimic oxygen transport[15][17].
   • Perfluorocarbon Emulsions: Synthetic oxygen carriers for trauma and military applications[14].
   • Stem Cell-Derived RBCs: Companies like Kedrion Biopharma invest in lab-grown RBCs to address donor shortages[2][14].

2. Plasma Fractionation:

   • Methods to isolate albumin, immunoglobulins, and clotting factors efficiently (e.g., US6986984)[15].

3. Automation Technologies:

   • Patents for automated blood processing systems to minimize contamination and improve yield[8].

Strategic Trends

• Collaborative R&D: Partnerships between academia and industry (e.g., Terumo’s work on synthetic RBCs)[14][17].
• Geographic Shifts: China and South Korea show rising patent filings in microfluidics for CTC isolation[14].

Legal Considerations

• Inventorship Disputes: Cases like Google v. IPA Technologies highlight the need to corroborate contributions in multi-author patents[4].
• Prior Art Challenges: Competitors increasingly use inter partes reviews to invalidate patents (e.g., Martin reference dispute)[4].

---

Future Outlook

• Synthetic Blood: The artificial blood market is projected to reach $17.8 billion by 2027 (27.8% CAGR)[14].
• Personalized Medicine: Tailored plasma therapies for rare diseases are driving patent activity[2][11].
• Regulatory Focus: Stricter safety protocols for storage and pathogen reduction (e.g., automated screening patents)[8][15].

Highlight: "Automation in blood processing reduces human errors by 40%, ensuring safer transfusions"[2].

---

Key Takeaways

1. The B05A market is expanding due to aging populations and trauma care needs.
2. Patent filings prioritize synthetic substitutes and automation to overcome donor dependency.
3. Asia-Pacific and biotech startups are emerging as innovation hubs.
4. Legal strategies are critical to navigating inventorship and prior art challenges.

For businesses, aligning R&D with patent trends in synthetic blood and AI-driven analytics will be vital to capturing market share[9][14].

References

1. https://www.ipcheckups.com/patent-landscape-analysis-how-to-5-steps/
2. https://straitsresearch.com/report/blood-market
3. https://www.theinsightpartners.com/reports/blood-products-market
4. https://www.jdsupra.com/legalnews/co-authorship-co-inventorship-but-can-4251240/
5. https://www.riziv.fgov.be/SiteCollectionDocuments/morse-report-2008-second-semester.pdf
6. https://www.prweb.com/releases/wifi-7-patent-landscape-analysis-by-greyb-huawei-qualcomm-mediatek-and-lg-competing-to-lead-302353076.html
7. https://www.towardshealthcare.com/insights/blood-product-market-sizing
8. https://www.verifiedmarketresearch.com/product/blood-product-market/
9. https://www.alliedmarketresearch.com/patent-analytics-market-A14628
10. https://www.globenewswire.com/news-release/2024/11/12/2979157/28124/en/Circulating-Tumor-Cells-Patent-Landscape-and-Forecast-2024-2032-The-U-S-Leads-with-Over-4-000-Patent-Filings-Driven-by-Robust-R-D-Infrastructure-and-Substantial-Investments-in-Canc.html
11. https://www.bccresearch.com/market-research/healthcare/global-markets-for-blood-plasma-products.html
12. https://en.wikipedia.org/wiki/ATC_code_B05
13. https://atcddd.fhi.no/atc_ddd_index/?showdescription=yes&code=B05AA
14. https://www.prweb.com/releases/artificial-blood-substitutes-market-worth-5-204-million-by-2022-843622504.html
15. https://patents.justia.com/patents-by-us-classification/530/829
16. https://pubchem.ncbi.nlm.nih.gov/compound/Dextran
17. https://patents.justia.com/patents-by-us-classification/514/832